1-11 of 11
Frank Totzke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 648: Relevance of substrate selection for the results of biochemical WEE1 in-vitro kinase activity inhibition assays

Daniel G. Mueller, Andreas Gericke, Frank Totzke, Carolin Heidemann-Dinger, Constance Ketterer, Diane Kraemer, Thomas Weber, Michael H. Kubbutat
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 648.
https://doi.org/10.1158/1538-7445.AM2024-648
Published: 22 March 2024
View article titled, Abstract 648: Relevance of substrate selection for the results of biochemical WEE1 in-vitro kinase activity inhibition assays
Journal Articles

Abstract 5980: Identification of CDK15 activating cyclins by a recombinant co-expression approach

Daniel Mueller, Constance Ketterer, Diane Kraemer, Carolin Heidemann-Dinger, Lena Pilgermayer, Thomas Weber, Andreas Gericke, Frank Totzke, Michael H. Kubbutat
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5980.
https://doi.org/10.1158/1538-7445.AM2023-5980
Published: 04 April 2023
View article titled, Abstract 5980: Identification of CDK15 activating cyclins by a recombinant co-expression approach
Journal Articles

Abstract 2304: Comprehensive characterization of CDK inhibitors using a complete panel of all 20 human cyclin-dependent kinases

Daniel Müller, Frank Totzke, Thomas Weber, Andreas Gericke, Diane Krämer, Carolin Heidemann-Dinger, Constance Ketterer, Michael H. Kubbutat
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2304.
https://doi.org/10.1158/1538-7445.AM2022-2304
Published: 15 June 2022
View article titled, Abstract 2304: Comprehensive characterization of CDK inhibitors using a complete panel of all 20 human cyclin-dependent kinases
Journal Articles

Abstract 4072: Cytotoxic effects of LRRK2 inhibitors in combined treatment with chemotherapeutic agents on a large panel of cancer cell lines

Franziska Fimm-Todt, Joachim Lauterwasser, Eva-Maria Egenter, Christian Weber, Daniel Feger, Katharina Schaich, Sarah Ulrich, Oliver Siedentopf, Frank Totzke, Michael Kubbutat, Jan Erik Ehlert
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4072.
https://doi.org/10.1158/1538-7445.AM2022-4072
Published: 15 June 2022
View article titled, Abstract 4072: Cytotoxic effects of LRRK2 inhibitors in combined treatment with chemotherapeutic agents on a large panel of cancer cell lines
Journal Articles

Abstract 2318: Real-time quantitative PCR based analysis of transcriptional effects of CDK8/Cyclin C inhibitors

Laura M. Jordt, Frank Totzke, Joachim Lauterwasser, Jan E. Ehlert, Koen Hekking, Bas Aerts, Cynthia Obodozie, Holger Weber, Gerhard Müller, Michael H. Kubbutat
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2318.
https://doi.org/10.1158/1538-7445.AM2022-2318
Published: 15 June 2022
View article titled, Abstract 2318: Real-time quantitative PCR based analysis of transcriptional effects of CDK8/Cyclin C inhibitors
Journal Articles

Abstract 2388: IC50 profiling against 320 protein kinases: Improving the accuracy of kinase inhibitor selectivity testing

Daniel Mueller, Frank Totzke, Thomas Weber, Marcel Pathe, Christoph Schaechtele, Michael H. Kubbutat
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2388.
https://doi.org/10.1158/1538-7445.AM2018-2388
Published: 01 July 2018
View article titled, Abstract 2388: IC50 profiling against 320 protein kinases: Improving the accuracy of kinase inhibitor selectivity testing
Journal Articles

Abstract 4186: A biochemical approach to discriminate between ATP-competitive and non-ATP competitive protein kinase inhibitors

Daniel Mueller, Frank Totzke, Thomas Weber, Carolin Heidemann-Dinger, Constance Ketterer, Diane Krämer, Marcel Pathe, Michael H. Kubbutat
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4186.
https://doi.org/10.1158/1538-7445.AM2017-4186
Published: 01 July 2017
View article titled, Abstract 4186: A biochemical approach to discriminate between ATP-competitive and non-ATP competitive protein kinase inhibitors
Journal Articles

Abstract 2821: Characterization of CDK inhibitors in a biochemical assay using a comprehensive panel of human CDK-cyclin complexes

Daniel Mueller, Frank Totzke, Thomas Weber, Christian Beisenherz-Huss, Diane Kraemer, Carolin Heidemann-Dinger, Constance Ketterer, Chris Eckert, Michael H.G. Kubbutat.
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2821.
https://doi.org/10.1158/1538-7445.AM2016-2821
Published: 15 July 2016
View article titled, Abstract 2821: Characterization of CDK inhibitors in a biochemical assay using a comprehensive panel of human CDK-cyclin complexes
Journal Articles

Abstract 4781: A comprehensive screen for protein kinases involved in histone phosphorylation using a biochemical in-vitro approach

Daniel Mueller, Frank Totzke, Constance Ketterer, Christian Beisenherz-Huss, Diane Krämer, Thomas Weber, Carolin Heidemann-Dinger, Michael H.G. Kubbutat
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4781.
https://doi.org/10.1158/1538-7445.AM2015-4781
Published: 01 August 2015
View article titled, Abstract 4781: A comprehensive screen for protein kinases involved in histone phosphorylation using a biochemical in-vitro approach
Journal Articles

Abstract 5168: Effects of point mutations, recombinant tags, activation status, and identity of target kinases on the mode of action of approved kinase inhibitors.

Daniel Müller, Christian Beisenherz-Huss, Frank Totzke, Carolin Heidemann-Dinger, Constance Ketterer, Thomas Weber, Michael H.G. Kubbutat
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 5168.
https://doi.org/10.1158/1538-7445.AM2013-5168
Published: 15 April 2013
View article titled, Abstract 5168: Effects of point mutations, recombinant tags, activation status, and identity of target kinases on the mode of action of approved kinase inhibitors.
Journal Articles

PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration

Jeanette M. Wood, Guido Bold, Elizabeth Buchdunger, Robert Cozens, Stefano Ferrari, Jörg Frei, Francesco Hofmann, Jürgen Mestan, Helmut Mett, Terence O’Reilly, Elke Persohn, Johannes Rösel, Christian Schnell, David Stover, Andreas Theuer, Harry Towbin, Fritz Wenger, Kathie Woods-Cook, Andreas Menrad, Gerhard Siemeister, Michael Schirner, Karl-Heinz Thierauch, Martin R. Schneider, Joachim Drevs, Georg Martiny-Baron, Frank Totzke, Dieter Marmé
Journal: Cancer Research
Cancer Res (2000) 60 (8): 2178–2189.
Published: 01 April 2000
View article titled, PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration
Open the PDF for PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration in another window